A New Role for Wilms Tumor Protein 1: Differential Activities of + KTS and –KTS Variants to Regulate LHβ Transcription

Debalina Bagchi1, Josefa Andrade2, Margaret A. Shupnik2*

1 Department of Cell Biology, University of Virginia School of Medicine, Charlottesville, Virginia, United States of America, 2 Department of Medicine, Division of Endocrinology, University of Virginia School of Medicine, Charlottesville, Virginia, United States of America

Abstract

Luteinizing hormone (LH) is synthesized and secreted throughout the reproductive cycle from gonadotrope cells in the anterior pituitary, and is required for steroidogenesis and ovulation. LH contains an α-subunit common with FSH, and a unique LHβ subunit that defines biological activity. Basal LHβ transcription is low and stimulated by hypothalamic GnRH, which induces synthesis of early growth response protein-1 (Egr1), and stimulates binding of transcription factors Egr1 and steroidogenic factor-1 (SF1) on the promoter. WT1 (Wilms tumor protein1) is a zinc finger transcription factor with an essential role in urogenital system development, and which regulates several reproductive genes via interactions with SF1 or binding to GC-rich elements such as Egr1 binding sites. We investigated a potential role for WT1 in LHβ transcription in clonal mouse gonadotrope LβT2 cells. WT1 was present in LβT2 and mouse pituitary cells, and protein bound to the endogenous LHβ promoter. Interestingly, mRNAs for WT1(+KTS), which contains a three amino-acid insertion between the 3rd and 4th zinc fingers, and the WT1 (-KTS) variant were both expressed at significant levels. WT1 mRNAs and protein were decreased approximately 50% by GnRH treatment, under conditions where Egr1 mRNA and protein, and LHβ transcription, were stimulated. Decreasing expression of mRNA for WT1 (-KTS) decreased stimulation of LHβ and Egr1 by GnRH, whereas decreasing both WT1 (-KTS) and (+KTS) increased endogenous LHβ transcription, and prevented LHβ but not Egr1 stimulation by GnRH, suggesting differing biological activities for the WT1 isoforms. Overexpression of WT1 showed that WT1(-KTS) enhanced LHβ promoter GnRH stimulation 2-to-3-fold and required the 3'Egr1 site, but WT1(+KTS) repressed both basal and GnRH-stimulated LHβ promoter activity by approximately 70%. Our data suggest that WT1 can modulate LHβ transcription, with differential roles for the two WT1 variants; WT1 (-KTS) enhances and WT1 (+KTS) suppresses transcription.

* mas3x@virginia.edu
Introduction

Gonadotropin hormones secreted from the anterior pituitary control female reproduction, and Luteinizing Hormone (LH) specifically is necessary for ovulation and steroidogenesis [1, 2]. LH consists of two subunits, an alpha subunit shared with FSH, and a unique beta subunit, which is limiting for the intact hormone [3]. Hypothalamic GnRH is a crucial modulator of the gonadotropin subunit genes, and among all the subunits LHβ is most dramatically and precisely regulated by GnRH [4, 5]. The LHβ promoter includes two GnRH responsive regions. The distal region contains two SP1 sites and a CArG box. The proximal GnRH response element, conserved across all mammalian species including humans, consists of two Egr1 (Early Growth Response 1), two SF1 (Steroidogenic Factor 1) binding sites, and a binding site for the homeobox protein Ptx1. Full transcriptional activation requires interactions and synergy between the distal and proximal response elements [6, 7]. Synthesis of the zinc-finger transcription factor Egr1 (early growth response 1) occurs rapidly in response to GnRH and is a critical component of increased LHβ transcription [8, 9, 10, 11]. SF1 is a nuclear receptor that regulates the transcription of several genes involved in steroidogenesis and reproduction, including the pituitary gonadotropin subunit genes and the GnRH receptor [12, 13, 14].

In response to GnRH, co-ordinated binding of transcription factors occurs on the LHβ promoter [10, 15]. These proteins in turn may associate with additional stimulatory and suppressive regulatory proteins, including SNURF [15], SRC-1 [16] and DAX-1 [17, 18] that influence the response of reproductive genes to hormonal and physiological challenges. The WT1 protein (Wilms Tumor protein 1) associates with Sp1, SF1 and DAX-1 to exert influence on many reproductive gene promoters including SF1 itself, and is essential for mammalian urogenital development and gonadogenesis prior to sexual differentiation [18, 19, 20, 21]. In addition, WT1 binds directly to DNA at GC-rich motifs similar to those for Egr1 or Sp1 [22, 23]. In spite of these intriguing associations with the transcription factors involved in LHβ gene transcription, the potential role of WT1 in LHβ gene transcription has not previously been examined.

WT1 has a broad range of target genes and can act as either a transcriptional repressor or activator, in a cell and promoter specific manner. For example, WT1 represses transcription of the human PDGF A chain [24], human telomerase reverse transcriptase [25], and proto-oncogenes bcl-2 and c-myc [26] genes, but stimulates the SF1 [18], DAX-1 [27], erythropoietin [28] and amphiregulin [29] genes. The WT1 gene has ten exons that encode a proline-glutamine rich amino terminal involved in protein-protein interactions, and four zinc-finger domains towards the carboxy-terminal end that bind DNA [19, 21]. There are several splice variants of WT1, the most common of which include +KTS and –KTS, variants resulting in the presence or absence of a three amino acid (KTS) insertion between the third and fourth zinc finger near exon 9 [21]. In this paper, we investigated the role of WT1 in LHβ transcription, addressing the individual roles of the WT1 (+KTS) and WT1 (-KTS) variants under basal and GnRH-stimulated conditions. Our data shows WT1 to be a novel regulator of LHβ and that the splice variants differentially regulate LHβ transcription. The +KTS variant represses both basal and GnRH stimulated LHβ transcription whereas the –KTS variant activates GnRH-stimulated LHβ transcription.

Materials and Methods

Cell culture, transient transfection and luciferase assay

Experiments were performed using the clonal mouse gonadotrope cell line, LβT2 as previously described [10]. Cells were maintained in Dulbeccos Minimal Essential Medium (DMEM) with 10%FBS (fetal bovine serum) and 1% antibiotic/antimycotic (GIBCO, Grand Island, New
York). For experiments, cells were plated in phenol red-free DMEM with 5% charcoal stripped serum and 2% L-glutamine. GnRH (50 nM, Bachem Biosciences Inc, King of Prussia, PA under the name LHRH) was used as indicated. LβT2 cells were plated using DMEM plus 5% charcoal stripped newborn calf serum at the concentration of 500,000 cells per well in 12-well (20 mm diameter) dishes. After 24h, the cells were transfected with a luciferase reporter construct driven by the rat LHβ promoter using Lipofectamine 2000 (Invitrogen; Carlsbad, California). For transfection experiments, 0.33 μg per reaction of the rat LHβ gene promoter from -617 to +44 bp (containing both distal and proximal GnRH responsive elements) or 1 μg per reaction of truncated promoter (-245 to +44 region containing only the downstream GnRH response element) fused to luciferase were used. In WT1 overexpression/dose response studies, increasing concentrations of WT1 (splice variants +KTS and –KTS) plasmid DNA up to 0.33 μg were transfected along with the reporter plasmid. Empty vector pCB6+ plasmid at various concentrations was transfected to keep total DNA constant. WT1 expression plasmids were a generous gift from Dr. Nicholas Webster, UCSD [30]. In some studies, the rat LHβ gene promoter from -617 to +44 bp with previously described mutations in either the SF1 sites or the Egr1 sites [6, 31] were used to define the requirement for these DNA regions in WT1 actions. After 48 h of transfection, the cells were treated with or without GnRH for 6 hrs and the cell lysates were collected in 200 μl of 1x passive lysis buffer (Promega, Madison, WI, cell culture lysis reagent). The samples were centrifuged at 13,000 rpm for 1 min and supernatant was collected. Luciferase activity was measured using a Turner TD-20e luminometer (Turner Designs, Mountain View, CA). Total proteins of each sample were measured using the Bradford Protein assay (Bio-Rad dye; Hercules, CA). Luciferase activity was normalized as described [10, 32]. Average and standard error were calculated for 6 samples. Statistical significance was determined using paired student T-test and ANOVA and with differences between treatment groups determined by Bonferroni multiple comparison test [31].

In some experiments, normal mouse pituitaries were used to measure WT1 mRNAs. Female mice were ovariectomized between 2–3 months of age; approximately 10–14 days post-ovariectomy, animals were treated with oil or 300 ng 17β-estradiol for 3 days as previously described [33, 34]. Animals were killed at 9AM and pituitaries collected for RNA purification and mRNA measurement as previously described [31, 32]. For in vitro GnRH treatment, pituitary cells from adult mice were treated in culture with 5 nM GnRH; WT1 mRNAs were measured and normalized for GAPDH mRNA [32].

**siRNA delivery and primary transcript assay**

To decrease expression of mRNAs and protein, siRNA was delivered into LβT2 cells using nucleofection technology according to the manufacturer’s instructions (Amaxa Corp., Gaithersburg, MD) and as previously described [32]. The LβT2 cells were nucleofected with siGENOME SMARTpool siRNA (0.2nM;Dharmacon RNA Technologies, Lafayette, CO) directed against mouse WT1 or a non-targeting negative control siRNA (0.2nM, siCON #1; Dharmacon), in Solution T and using Program A-020. Each reaction contained 5 × 10⁶ cells and was divided between three wells in a 35-mm plate containing 2 ml 5% SNCS. Cell lysates were collected after 72 h for primary transcript assay for LHβ, RT-PCR to detect WT1 mRNA isoforms, and immunoblotting to confirm WT1 knockdown. Experiments were performed in triplicate three times. Protein levels were analyzed on immunoblots.

To measure specific mRNAs, RNA was isolated from the cell lysates using the QIAGEN (Valencia, CA) RNAsesy kit and was briefly treated with DNase (Roche, Indianapolis, IN) to remove DNA contamination. Total RNA was subjected to reverse transcription of the mRNA using the iScript cDNA synthesis kit (Bio-Rad). Quantitative real-time PCR was performed.
using cDNA as template, as described [31, 32]. Primers were designed against the first intron/exon border of the mouse LHβ gene to detect unspliced mRNA primary transcript (PT) (forward primer sequence, 5'-AGAGGCTCCAGTAAAGATGTA-3'; reverse primer sequence, 5'-CCACTAGTATAATACAGAAAC-3'). Egr1 primary transcript mRNA was measured as previously described [10, 32]. Both Egr1 and LHβ primary transcript mRNAs were normalized to GAPDH mRNA levels. Samples without the reverse transcriptase enzyme during cDNA synthesis were used as negative controls. In results, five representative experiments among seven experiments are shown. To measure expression of WT1 (splice variants +KTS and –KTS) mRNA, cells were treated with vehicle or 50 nM GnRH for 90 min, RNA was isolated and quantitative PCR was performed. The WT1 primers used were: forward primer sequence, 5'-CATCTGAAACCAGTGAAACG-3' for -KTS, reverse primer sequence for +KTS, 5'-CTCATAGGTAAAAGCCCTT-3'. All mRNAs were normalized to GAPDH mRNA levels. Averages and SEM were calculated from PCR replicates.

**Western Blot**

For Western blot analysis, 2 x 10^6 cells per well were plated in 6-well 35 mm dishes. After 24h, cells were treated with 50 nM GnRH and collected every 30 min for 3.5 h. Cells were lysed and collected using 2x gel loading buffer [100 mM Tris-HCL (pH 6.8), 4% SDS, 20% glycerol] plus protease inhibitors as described by Andrade et al. [32], and the protein concentration was measured using the Pierce (Rockford, IL) BCA Kit. Cell lysates were heated for 5 min at 95°C and equal amounts of proteins of each sample were separated by 10% SDS-PAGE using 140V constant voltage for approximately 2 h. Proteins were transferred to a nitrocellulose membrane using 35V constant voltage for 3 h. Membranes were then blocked using 10% non-fat dry milk in Tris-buffered saline plus 1% Tween 20 (TBST) for 1h in room temperature. Membranes were then incubated with a WT1 primary antibody (C-19:SC-192 Santa Cruz Biotechnologies, Santa Cruz CA) overnight (1:500) or Egr1 primary antibody (Cell Signaling Technology) overnight (1:1000) at 4°C followed by three 5 min washes with TBST and another incubation with secondary antibody, horseradish peroxidase-conjugated donkey anti-rabbit Fab fragment IgG (1:5000;GE HealthCare; Piscataway, New Jersey) for 2h. Relative levels of proteins were detected with ECL, SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL) and X-ray film autoradiography. Monoclonal anti-β-actin primary antibody (Sigma) was used as a loading control to re-probe the membrane. Band intensity was measured by densitometry and normalized against β-actin in the same samples.

**Chromatin Immunoprecipitation**

Assays were performed as previously described [10, 31]. To measure WT1 promoter occupancy under basal conditions (without GnRH treatment), LβT2 cells were pre-treated with 2.5 μM of α-amanitin for 1h followed by thorough washing with PBS and incubation with phenol red-free DMEM with 5% charcoal stripped serum and 2%L-glutamine for 20 min. For GnRH studies, LβT2 cells were first pre-treated with 2.5 μM of α-amanitin for 1h to synchronize protein occupancy on the promoter, washed, then incubated in fresh media with or without 50 nM GnRH and two plates of cells collected every 10 min for 2h. Chromatin immunoprecipitation (ChIP) assays were performed by cross-linking the chromatin from each collected sample with 1% formaldehyde for 10 min; the reaction was stopped by addition of 1.25 M glycine and cells were collected in cold PBS plus protease inhibitors [10, 31]. Cross-linked chromatin was sonicated to approximate lengths of 1000 bp, using a cup horn sonicator (Misonix, Farmingdale, NY). Whole-cell extract was diluted with ChIP sonication buffer plus protease inhibitors,
WT1 (−KTS) and (+KTS) Variants Differentially Regulate the LHβ Gene

Ethics Statement

LβT2 cells were obtained from Dr. Pamela Mellon, University of California, San Diego, who originally developed the line and described their use [35]. Cells were obtained in 1999, at at passage 14, and immediately split into multiple flasks to freeze and keep as close to the original founder line as possible; each thaw is accompanied by a similar round of propagation and freezing and cells are not continuously propagated. Recent studies were performed with cells thawed from passages between 19–21. Cells are thawed in Dulbecco’s Minimal Essential Medium (DMEM) with 10%FBS (fetal bovine serum) and 1% antibiotic/antimycotic (GIBCO, Grand Island, New York), and have been tested periodically to ensure no micoplasma contamination.

Results

WT1 is expressed in LβT2 cells and associates with the LHβ promoter

To determine if the common WT1 variants WT1 (−KTS) and WT1 (+KTS) are expressed in LβT2 cells, we first measured WT1 mRNAs by RT-PCR, using specific primers to detect the splice variants. The amplified products, separated on a 1% agarose gel, (Fig. 1A) show bands that correspond to expected sizes for both +KTS (301 bp) and −KTS (292 bp) products; no PCR product was detected without reverse transcriptase either on a gel (not shown) or by incorporation of Syber Green into PCR product (Fig. 2). WT1 protein is also expressed under basal (without GnRH) conditions in LβT2 cells, whereas Egr1, a zinc-finger transcription factor proven to associate with the LHβ promoter, is not expressed at detectable levels under the same conditions (Fig. 1B). Only one specific protein band for WT1 was observed, as expected, as the three amino acid difference cannot be detected by electrophoresis. To determine if WT1 could bind to the endogenous LHβ promoter, chromatin immunoprecipitation assays were performed in untreated LβT2 cells. Under basal conditions (Fig. 1C), both WT1 and phosphorylated RNA Polymerase II associate with the promoter, suggesting that WT1 may play a role in regulating transcription.

GnRH decreases WT1 mRNA and Protein

The most critical regulatory pathway for LHβ is through GnRH, which induces synthesis of the early response gene and transcription factor Egr1; Egr1 then binds to GC-rich DNA motifs similar to those for Sp1 and WT1 and stimulates transcription [10, 36, 37]. To investigate if
WT1 is also regulated by GnRH, LβT2 cells were treated with or without GnRH for 90 min and WT1 (+KTS, -KTS) mRNA levels and WT1 protein levels were measured. **Fig. 2** shows that GnRH actually reduces the mRNA levels of both the WT1 splice variants by approximately 50%. Over 10–12 experiments, the relative amounts of +/-KTS variants that were expressed varied somewhat between experiments, as did the degree of GnRH suppression. However, overall the two mRNA variants are both expressed under basal conditions and regulated by GnRH, on average, to the same extent.

We also compared GnRH effects on the protein expression levels of both WT1 and Egr1 in the same experiment. LβT2 cells were treated with GnRH over a period of 0–3.5 h. WT1 or Egr1 proteins were measured by immunoblotting, then normalized to β-actin levels and quantified by densitometric analysis. **Fig. 2** shows that WT1 is easily detected in cells without GnRH stimulation, when Egr1 is not expressed. In the presence of GnRH, WT1 protein levels are decreased by approximately 50%, within 30–60 min, but is maintained at this level between...
3–3.5h. In contrast, Egr1 protein is transiently and robustly stimulated within 30 min of GnRH treatment, with highest expression levels by 1 h of GnRH. Thus, GnRH differentially regulates WT1 and Egr1, by suppressing WT1 and stimulating Egr1 expression.

**GnRH stimulates WT1 and Egr1 association with the LHβ promoter**

GnRH stimulates the binding of transcription factors and co-regulatory proteins on the LHβ promoter [10]. Since GnRH regulates the mRNA and protein expression levels of Egr1 and WT1, we investigated how GnRH might regulate WT1 association with the LHβ promoter by performing chromatin immunoprecipitation assays in the presence of GnRH (Fig. 3). In the presence of GnRH, transcription factors and RNA Pol II associate with the promoter in a rhythmic fashion, with an interval time of approximately 30 min [10]; both WT1 and pRNA
Pol II show this pattern of association. Egr1 is recruited to the promoter with a similar pattern, but with a somewhat delayed association. Maximal Egr1 association required more than 30 min, reaching highest values at 60 min, correlating with the time needed for GnRH-stimulated synthesis, between 30 and 60 min (as in Fig. 2). Thus, WT1 may modulate LHβ transcription at times when Egr1 is present or absent on the promoter.

Reduced levels of endogenous WT1 influence basal and GnRH-stimulated endogenous LHβ gene transcription

To further investigate a potential role for WT1 on endogenous LHβ gene transcription, we decreased endogenous WT1 expression via targeted knock-down by siRNA. A non-targeting
siRNA was used in parallel as a control. After 72 h of siRNA treatment, cells were incubated with GnRH for 90 min, and LHβ primary transcript mRNA was measured. As shown in Fig. 4A, knock-down of WT1(-KTS) mRNA alone reduced endogenous WT1 protein by approximately 50%. Under these conditions, basal LHβ mRNA transcription was not significantly affected, but GnRH-stimulated transcription was suppressed by approximately 50%. When both mRNA isoforms for WT1 were decreased, with endogenous WT1 protein decreased by >90% (Fig. 4B), basal LHβ transcription was significantly increased (approximately 2-fold) compared to siControl, and GnRH treatment resulted in lower LHβ primary transcript levels compared to siControl GnRH, or siWT1 cells treated with vehicle. Because WT1 is a transcriptional regulator, and because Egr1 expression is important for LHβ transcription, we also tested the effects of WT1 variant knock-down on the basal and GnRH-stimulated expression of Egr1 mRNA. Interestingly, knock-down of WT1(-KTS) alone reduced GnRH stimulation of Egr1 mRNA by approximately 60%, similar to the suppression of GnRH-stimulated LHβ transcription. In contrast, knock-down of both WT1 isoforms does not suppress Egr1 expression, and
GnRH stimulation of Egr1 occurs even though LHβ transcription is not stimulated by GnRH. These data suggest that there may be different, and perhaps even opposing, biological roles for the two WT1 variants on LHβ transcription.

WT1 +KTS and WT1-KTS variants differentially regulate LHβ promoter activity

To directly test the role of the WT1 +KTS and –KTS splice variants in LHβ transcription, basal and GnRH-stimulated activity of the LHβ promoter (-617 to +44 bp) was measured in the absence or presence of increasing amounts of WT1(+KTS) or WT1(-KTS) expression vectors. WT1(-KTS) overexpression significantly increased the GnRH stimulation of LHβ promoter activity by approximately 3- to 4-fold at the highest concentrations (Fig. 5A). The -617LHβ promoter contains two regions that might be influenced by WT1, including the distal enhancer that contains Sp1 binding sites, and the proximal enhancer containing Egr1 binding sites; both are required for effective GnRH-stimulated transcription to occur [6, 7]. We thus assessed whether WT1 was able to influence LHβ transcription through the proximal enhancer containing Egr1 binding sites; both are required for effective GnRH-stimulated transcription to occur [6, 7]. We thus assessed whether WT1 was able to influence LHβ transcription through the proximal enhancer containing Egr1 binding sites; both are required for effective GnRH-stimulated transcription to occur [6, 7]. We thus assessed whether WT1 was able to influence LHβ transcription through the proximal enhancer containing Egr1 binding sites; both are required for effective GnRH-stimulated transcription to occur [6, 7]. We thus assessed whether WT1 was able to influence LHβ transcription through the proximal enhancer containing Egr1 binding sites; both are required for effective GnRH-stimulated transcription to occur [6, 7]. We thus assessed whether WT1 was able to influence LHβ transcription through the proximal enhancer containing Egr1 binding sites; both are required for effective GnRH-stimulated transcription to occur [6, 7]. We thus assessed whether WT1 was able to influence LHβ transcription through the proximal enhancer containing Egr1 binding sites; both are required for effective GnRH-stimulated transcription to occur [6, 7]. We thus assessed whether WT1 was able to influence LHβ transcription through the proximal enhancer containing Egr1 binding sites; both are required for effective GnRH-stimulated transcription to occur [6, 7]. We thus assessed whether WT1 was able to influence LHβ transcription through the proximal enhancer containing Egr1 binding sites; both are required for effective GnRH-stimulated transcription to occur [6, 7].
WT1 effects. To directly test if the WT1 variants act through the same or different DNA elements, LHβ promoter (-617 to +44 bp) luciferase constructs containing mutations specifically in both 5' and 3'-SF1 sites, or individual 3'- or 5'-Egr1 sites, were tested for the response to WT1 variant overexpression in the presence or absence of GnRH. As seen in Fig. 7, mutation of the 3'-Egr1 site, but not the SF1 sites, in the LHβ promoter abrogated the effects of the WT1 (-KTS) variant. In contrast, mutation of the SF1 sites or the 3'-Egr1 site eliminated the effects of the WT1 (+KTS) variant on the LHβ promoter (Fig. 8). Thus, WT1 (-KTS) appears to mediate its effects exclusively through the Egr1 site, whereas the WT1 (+KTS) variant requires both Egr1 sites and SF1 sites for its biological effects.

Expression and regulation of WT1 variants in normal mouse pituitary

To test if WT1 variants are expressed and regulated in normal gonadotrope cells in addition to the clonal mouse gonadotrope cell line, mRNA was collected from mouse pituitary cells under different physiological conditions and WT1 mRNA variants were measured. As shown in Fig. 9, both WT1 variants were expressed in pituitary glands from ovariectomized female mice (upper panel). WT1 (-KTS) expression was highest in ovariectomized mice treated with 17β-estradiol compared to those treated with vehicle alone. WT1 (-KTS) mRNA was not significantly changed between the two groups, although the trend was to lower expression in pituitary cells from ovariectomized mice. Interestingly, lower expression of WT1 (+KTS) in ovariectomized females versus treatment of ovariectomized mice with E2 correlates with more robust GnRH pulse patterns noted in ovariectomized animals [3]. In mouse pituitary cells treated in culture with GnRH (lower panel), WT1 (-KTS) mRNA levels were decreased approximately 75% by GnRH, while WT1 (+KTS) mRNA was not significantly changed with GnRH treatment.

Discussion

In this work, we show for the first time that WT1 regulates LHβ transcription, and that the -KTS and +KTS have differential roles in this regulation. The function of WT1 is well established in the urino-genital (kidney and gonads) system [18, 19, 20, 21], but its role has been

Fig 6. WT1 (+KTS) decreases basal and GnRH-stimulated LHβ promoter activity. LBT2 cells were transfected with either A) A luciferase reporter construct driven by the rat LHβ promoter (-617 to +41 bp) including both distal and proximal GnRH responsive promoter regions, or B) A luciferase reporter construct driven by the rat LHβ promoter (-245 to +44 bp), including only the proximal GnRH response region of the promoter. Constructs were cotransfected with or without 0.5, 0.7, 1 μg of WT1 (+KTS) plasmid or control plasmid to normalize DNA. At 48 h post-transfection, cells were treated with 50nM GnRH for 6 h and collected in lysis buffer. Luciferase activity was measured, and data expressed as average ± SE for 6 samples; the experiment was performed 3 times each. Statistical significance was determined using ANOVA (confidence interval determined by the Bonferroni multiple comparison test). * p<.05 -GnRH vs +GnRH, # = p<.05 control, -GnRH vs -GnRH+WT1, a = p<.05 control, +GnRH vs +GnRH +WT1.

doi:10.1371/journal.pone.0116825.g006
largely unexplored in the pituitary. We demonstrate that WT1 is expressed in LβT2 cells, an immortalized mouse gonadotrope cell line, is regulated by GnRH (Fig. 1 and Fig. 2), binds to the LHβ promoter, and regulates promoter activity. Both WT1 mRNA variants are expressed in normal mouse pituitary (Fig. 9) and the WT(-KTS) isoform also appears to be significantly regulated by GnRH.

As a Zinc-finger transcription factor, WT1 binds to GC-rich regions common to Egr1 and SP1, but often under different physiological conditions or with different biological outcomes [21, 22, 23, 37]. For example, WT1 and Egr1 have been shown to regulate the expression of the STIM1 gene by competing for one of the common binding sites on the STIM1 promoter. Egr1 stimulates STIM1 expression and WT1 antagonizes this effect by binding to Egr1 binding sites.
In addition, co-ordination of the differential binding pattern of the transcription factors WT1, Egr1, and Sp1 in a time-dependent manner was shown to be involved in the regulation of the α Isoform of the human thromboxane A2 receptor during megakaryocyte differentiation [23]. In response to PMA, there is an initial induction of Egr1 and reduction of WT1 association with this promoter, followed by SP1 occupancy after sustained PMA treatment [23].

Our data demonstrates mRNA expression of the two most prevalent WT1 splice variants, -KTS and +KTS, and presence of the WT1 protein in untreated cells (Fig. 1). Chromatin immunoprecipitation (ChIP) assays showed the association of WT1 to LHβ promoter in untreated cells, suggesting that WT1 could modulate basal LHβ expression (Fig. 1). The differential regulation of WT1 and Egr1 by GnRH in LβT2 cells (Fig. 2), suggests that Egr1 and WT1 may play somewhat different roles in LHβ expression. WT1, but not Egr1, was found to be expressed in untreated cells, and while Egr1 protein is dramatically induced by GnRH, WT1 protein is reduced by approximately 50%. GnRH stimulates LHβ transcription, and induces cyclic binding of the transcription factors Egr1 and SF1, and RNAPol II, on the LHβ promoter to drive transcription.

Fig 8. Differential responses of LHβ promoter mutants to WT(+KTS). LHβ promoter mutants were transfected into LβT2 cells with or without 1μg of WT1 (+KTS) plasmid or control plasmid to normalize DNA. Data were analyzed and expressed as in Fig. 7.
In this work, we showed that GnRH stimulates the cyclic association of both WT1 and Egr1 to the LHβ promoter, but Egr1 occupancy lags that of WT1 as GnRH must first stimulate Egr1 protein synthesis (Fig. 3). These data suggest involvement of WT1 in GnRH-stimulated LHβ transcription as well. There is currently no antibody that distinguishes between the WT1(-KTS) and WT1(+KTS) variants, and we cannot distinguish if both variants are binding to the promoter, or if one variant binds preferentially under basal or GnRH-stimulated conditions, by this method.

When we performed siRNA knock-down studies, knock-down of WT1(-KTS) mRNA alone did not significantly alter basal LHβ mRNA transcription, measured by levels of LHβ primary transcript mRNA, but decreased GnRH-stimulated transcription by approximately 50%, correlating with decreases in Egr1 mRNA primary transcript under the same conditions (Fig. 4A). In comparison, overexpression of WT1(-KTS) significantly increased GnRH stimulation of LHβ promoter activity by approximately 3-to 4-fold at the highest concentrations (Fig. 5); a small but significant increase in basal expression was also noted with the smaller promoter.
construct containing Egr1 sites and the proximal GnRH response region. Based on mutation data (Fig. 7) only the 3' Egr1 site, and not SF1 sites, is required for WT1(-KTS) activity on LHβ. This is in keeping with a positive role for WT1(-KTS) in LHβ transcription, via Egr1 expression and Egr1 binding sites. The Egr1 promoter contains GC-rich motifs that bind Egr1 [38] and potentially other related transcription factors such as WT1, so WT1(-KTS) regulation of this gene may be direct.

In contrast, when both mRNA isoforms for WT1 were decreased, and endogenous WT1 protein decreased by >95% (Fig. 4B), basal LHβ transcription was significantly increased (approximately 2-fold), and GnRH treatment decreased transcription below basal levels (Fig. 4B). GnRH-stimulated Egr1 primary transcript mRNA was not reduced, as was the case when only WT1(-KTS) was knocked down. WT1(+KTS) may antagonize the effects of WT1(-KTS) on Egr1 expression directly, or act via other genes and pathways. Overexpression of WT1(+KTS) alone decreased both basal and GnRH-stimulated LHβ promoter activity (Fig. 6) and required both the 3'-Egr1 site and the SF1 sites in the LHβ promoter (Fig. 8).

These data suggest a scenario in which WT1(+KTS) acts to suppress LHβ, while WT1(-KTS) acts primarily to enhance GnRH stimulation of LHβ promoter activity (Fig. 10). WT1 binding to the LHβ promoter under basal (no GnRH) conditions could help maintain low promoter activity, and WT1 is associated with the promoter in the absence of GnRH (Fig. 1). WT1(-KTS) would have positive effects on the promoter, while WT1(+KTS) would be suppressive, and there may be competition between the two isoforms for association with the LHβ promoter at the same gene site. Because WT1 exerts its actions only via the 3'-Egr1 site, stimulated Egr1 expression in the presence of GnRH would presumably result in more effective promoter occupancy at both Egr1 sites, and greater LHβ transcription. This is consistent with the lesser ability of WT1(-KTS) alone to increase LHβ promoter activity compared to promoter stimulation with GnRH (Fig. 5), and the ability of Egr1 overexpression to effectively substitute for GnRH in stimulating LHβ promoter activity [10, 32]. Interestingly, WT1(-KTS) appears to be more tightly regulated in normal pituitary cells (Fig. 9). GnRH treatment would decrease expression of the repressor WT1(-KTS) and the stimulator WT1(+KTS), but because Egr1 is more effective on LHβ than WT1(-KTS), overall LHβ promoter activity will be much higher.

The failure of GnRH to stimulate LHβ with complete WT1 protein knock-down in Fig. 4 is less straightforward. Increased basal activity may occur due to loss of suppression by WT1 (+KTS), but changes in Egr1 are not sufficient to explain this result and both WT1 isoforms may regulate other genes and pathways that could influence LHβ transcription. The +KTS variant was shown to be involved in RNA processing and RNA metabolism [44], but a recent report showed that +KTS can also bind to DNA on the planar cell polarity gene promoter SCRIBBLE and regulate its transcription in developing kidney [45]. WT1 acts synergistically with the transcription factor SF1 to regulate the expression of the Mullerian inhibiting substance gene during development of male gonads [18], and to regulate the expression of α-inhibin in Sertoli cells [39]. Both DNA binding and protein-protein interactions with SF1 may play a role in LHβ promoter regulation by WT1(+KTS), and additional protein-protein interactions could also contribute to these biological effects.

Differential regulation of transcription by the two WT1 splice variants has been noted for some other genes. For example, WT1+KTS strongly represses the insulin receptor promoter, whereas repression by WT1−KTS is more moderate and occurs only in the presence of additional C/EBPβ or a dominant negative p53 [30]. The −KTS splice variant of WT1 has been shown to stimulate α-inhibin expression in Sertoli cells of the testis but the +KTS variant had no such effect [39]. For LHβ, the two variants appear to have opposing roles in transcription, and the relative balance between the two forms may be crucial. Interestingly, mutations in intron 9 of the WT1 gene, where alternative splicing to generate WT1+KTS and −KTS occurs,
result in Frasier syndrome, including sex reversal and developmental defects in kidney and gonads [40, 41, 42, 43]. Mutations in some Frasier syndrome patients result in the predicted decrease of the WT1(+KTS) isoform and diminution of the WT1 (+KTS/-KTS) isoform ratio [40, 41]. Given the crucial role of WT1 in development of the reproductive organs and urogenital tract, and the necessary feedback between steroids on the hypothalamus and pituitary, studies to evaluate a potential role of WT1 mutations on pituitary function are difficult. However, a WT1 mutation (IVS9+5G>A) that causes Frasier syndrome has also been linked to hypergona
dotrophic hypogonadism and increased serum levels of gonadotropins (LH and FSH) in patients [42]. In at least one patient with a WT1 mutation (IVS9+4C>T) and high basal LH, both a decrease in the WT1(+KTS) and an increase in the WT1(−KTS) isoforms was observed [43]. These observations are in agreement with the increase in basal LH transcription observed in our siRNA studies when knock-down of both WT1 +KTS and −KTS WT1 occurred, and not when only the WT1(−KTS) variant was reduced.

Overall our data indicate that the WT1(+KTS) and (−KTS) splice variants play a differential and opposing role in regulating LHβ transcription. The role of WT1 as an activator or repressor seems to be context and promoter specific, and could also be influenced by the ratio of its splice variants if they exert opposing effects on the same promoter. The proximal GnRH responsive element region containing the two Egr-1 binding sites, and the two SF1 binding sites, is sufficient to exert the effects of WT1, and this region of the promoter is identical in rodents.
and humans [37]. Both direct WT1 binding to DNA and protein-protein association with SF1 play a role in WT1 function in this system. The two splice variants (-KTS and +KTS) of WT1 acting as a positive and negative regulator, respectively, to regulate LHβ gene transcription, defines a novel regulatory role of WT1 in pituitary gonadotropes and the reproductive system.

Acknowledgments

The authors would like to thank Dr. Nicholas Webster, University of California at San Diego, for the WT1 (+KTS) and (-KTS) expression vectors, and Dr. Pamela Mellon, University of California at San Diego, for the LβT2 cells.

Author Contributions

Conceived and designed the experiments: DB JA MAS. Performed the experiments: DB JA. Analyzed the data: DB JA. Contributed reagents/materials/analysis tools: DB JA. Wrote the paper: DB JA MAS.

References

1. Ferris HA, Shupnik MA (2006) Mechanisms for pulsatile regulation of the gonadotropin subunit genes by GNRH1. Biol Reprod 74: 993–998. doi:10.1095/biolreprod.105.049049 PMID: 16481992
2. Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352: 1223–1236. doi:10.1056/NEJMr041536 PMID: 15788499
3. Gharib SD, Wierman ME, Shupnik MA, Chin WW (1990) Molecular biology of the pituitary gonadotropins. Endocr Rev 11:177–199. doi: 10.1210/edrv-11-1-177 PMID: 2108012
4. Haisenleder DJ, Dalkin AC, Ortolano GA, Marshall JC, Shupnik MA (1991) A pulsatile gonadotropin-releasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency in vivo. Endocrinology 128: 509–517. doi: 10.1210/endo-128-1-509 PMID: 1702704
5. Shupnik MA (1990) Effects of gonadotropin-releasing hormone on rat gonadotropin gene transcription in vitro: requirement for pulsatile administration for luteinizing hormone-beta gene stimulation. Mol Endocrinol 4: 1444–1450. doi: 10.1210/mend-4-10-1444 PMID: 2126592
6. Weck J, Anderson AC, Jenkins S, Fallest PC, Shupnik MA (2000) Divergent and composite gonadotropin-releasing hormone-responsive elements in the rat luteinizing hormone subunit genes. Mol Endocrinol 14:472–485. doi: 10.1210/mend.14.4.0453 PMID: 10770486
7. Kaiser UB, Halvorson LM, Chen MT (2000) Sp1, steroidogenic factor 1 (SF-1), and early growth response protein 1 (Egr-1) binding sites form a tripartite gonadotropin-releasing hormone response element in the rat luteinizing hormone-β gene promoter: an integral role for SF-1. Mol Endocrinol 14:1235–1245. doi: 10.1210/mend.14.8.0507 PMID: 10935547
8. Halvorson LM, Kaiser UB, Chin WW (1999) The protein kinase C system acts through the early growth response protein 1 to increase LHβ gene expression in synergy with steroidogenic factor-1. Mol Endocrinol 13:106–116. doi: 10.1210/endo.13-1.0216 PMID: 9892016
9. Tremblay JJ, Drouin J (1999) Egr-1 is a downstream effector of GnRH and synergizes by direct interaction with Ptx1 and SF-1 to enhance luteinizing hormone β gene transcription. Mol Cell Biol 19: 2567–2576. PMID: 10082522
10. Walsh HE, Shupnik MA (2009) Proteasome regulation of dynamic transcription factor occupancy on the GnRH-stimulated luteinizing hormone β-subunit promoter. Mol Endocrinol 23:237–250. doi: 10.1210/me.2008-0098 PMID: 19095772
11. Lee SL, Sadovsky Y, Swirnoff AH, Polish JA, Goda P, et al. (1996) Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-Â (Egr-1). Science 273:1219–1221. doi: 10.1126/science.273.5279.1219 PMID: 8703054
12. Zhao L, Bakke M, Krimkevich Y, Cushman LJ, Parlow AF, et al. (2001) Steroidogenic factor 1 (SF1) is essential for pituitary gonadotrope function. Development 128: 147–154. PMID: 11124111
13. Schimmer BP, White PC (2010) Minireview: Steroidogenic Factor 1: Its roles in differentiation, development, and disease. Mol Endocrinol 24: 1322–1337. doi: 10.1210/me.2009-0519 PMID: 20203099
14. Dorn C, Ou QL, Svaren J, Crawford PA, Sadovsky Y (1999) Activation of luteinizing hormone-β gene by gonadotropin-releasing hormone requires the synergy of early growth response-1 and steroidogenic factor-1. J Biol Chem 274: 13870–13876. doi: 10.1074/jbc.274.20.13870 PMID: 10318795
15. Curtin D, Ferris HA, Hakli M, Gibson M, Janne OA, et al. (2004) Small nuclear RING finger protein stimulates the rat luteinizing hormone-β promoter by interacting with Sp1 and steroidogenic factor-1 and protects from androgen suppression. Mol Endocrinol 18: 1263–1276. doi: 10.1210/me.2003-0221 PMID: 14988433

16. Dammer EB, Leon A, Sewer MB (2007) Coregulator exchange and sphingosine-sensitive cooperativity of steroidogenic factor-1, general control nonderepressed 5, p54, and p160 coactivators regulate cyclic adenosine 3’, 5’-monophosphate-dependent cytochrome P450c17 transcription rate. Mol Endocrinol 21: 415–438. PMID: 17121866

17. Crawford PA, Dom C, Sadowsky Y, Milbrand J (1998) Nuclear receptor DAX-1 recruits nuclear receptor corepressor N-CoR to steroidogenic factor 1. Mol Cell Biol 18: 2949–2956. PMID: 9566914

18. Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JN, Hammer G, et al. (1995) Regulation of the Proto-oncogene β2 Tumor Suppressor Gene WT1. Cancer Res 55: 5386–5389. PMID: 9566914

19. Hohenste P, Haste ND (2006) The many facets of the Wilms’ tumour gene, WT1. Human Molecular Genetics 15: 196–201. doi: 10.1093/hmg/ddi196

20. Wilhelm D, Englert C (2002) The Wilms tumor suppressor WT1 regulates early gonad development by activation of SF1. Genes Dev 16: 1839–1851. doi: 10.1101/gad.220102 PMID: 12130543

21. Huff V (2011) Wilms’ tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nature Reviews Cancer 11: 111–121. doi: 10.1038/nrc3002 PMID: 21248786

22. Hamilton TB, Barilla KC, Romaniuk PJ (1995) High affinity binding sites for the Wilms tumour Suppressor Protein WT1. Nucleic Acids Research 23: 277–284. doi: 10.1093/nar/23.2.277 PMID: 7862533

23. Gannon AM, Turner EC, Reid HM, Kinsella BT (2009) Regulated Expression of the Wilms Tumor Suppressor Gene WT1. Cancer Res 65: 4290–4295. doi: 10.1158/0008-5472 can-08-3443 PMID: 19390329

24. Gashler AL, Bonthron DT, Madden SL, Rauscher FJ, Collins T, et al. (1992) Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci USA 89: 10984–10988. doi: 10.1073/pnas.89.22.10984 PMID: 1332065

25. Oh S, Song Y, Yim J, Kim TK (1999) The Wilms’ tumour 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase Gene. J Biol Chem 274: 37473–37478. doi: 10.1074/jbc.274.52.37473 PMID: 10601322

26. Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ, Saunders GF (1995) Regulation of the Proto-oncogenes bcl-2 and c-myc by the Wilms tumor Suppressor Gene WT1. Cancer Res 55: 5386–5389. PMID: 7585606

27. Kim J, Prawitt D, Bardeesy N, Torban E, Vicarelli C, et al. (1999) The Wilms’ tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation. Mol Cell Biol 19: 2289–2299. PMID: 10022915

28. Dame C, Kirschner KM, Bartz KV, Wallach T, Hussels CS, et al. (2006) Wilms tumor suppressor, WT1, is a transcriptional activator of the erythropoietin gene. Blood 107: 4282–4290. doi: 10.1182/blood-2005-07-2889 PMID: 16467207

29. Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, et al. (1999) The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 98: 663–673. doi: 10.1016/S0092-8674(00)80053-7 PMID: 10490105

30. Webster NJ, Kong Y, Sharma P, Haas M, Sukumar S, et al. (1997) Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter. Biochem Mol Med 62: 139–150. doi: 10.1006/bmm.1997.2648 PMID: 9441865

31. Ferris HA, Walsh HE, Stevens J, Fallest PC, Shupnik MA (2007) Luteinizing hormone beta promoter stimulation by adenylyl cyclase and cooperation with gonadotropin-releasing hormone 1 in transgenic mice and LβT2 cells. Biol Reprod 77: 1073–1080. doi: 10.1095/biolreprod.107.064139 PMID: 17699734

32. Andrade PC, Trader GL, Darrow JM, Shupnik MA (1995) Regulation of rat luteinizing hormone beta gene expression in transgenic mice by steroids and a gonadotropin-releasing hormone antagonist. Biol Reprod 53:103–109. doi: 10.1095/biolreprod53.1.103 PMID: 7669840
35. Turgeon JL, Kimura Y, Waring DW, Mellon PL (1996) Steroid and pulsatile gonadotropin-releasing hormone (GnRH) regulation of luteinizing hormone and GnRH receptor in a novel gonadotrope cell line. Mol Endocrinol 10:439–450. doi: 10.1210/mend.10.4.8721988 PMID: 8721988

36. Call GB, Wolfe MW (2002) Species differences in GnRH activation of the LHbeta promoter: role of Egr1 and Sp1. Mol Cell Endocrinol 189:85–96. doi: 10.1016/S0303-7207(01)00744-4 PMID: 12039067

37. Ritchie MF, Yue C, Zhou Y, Houghton PJ, Soboloff J (2010) Wilms tumor suppressor 1 (WT1) and early growth response 1 (EGR1) are regulators of STIM1 expression. J Biol Chem 285:10591–10596. doi: 10.1074/jbc.M109.083493 PMID: 20123987

38. Sakamoto KM, Bardeleben C, Yates KE, Raines MA, Golde DW, et al. (1991) 5’ upstream sequence and genomic structure of the human primary response gene, EGR-1/TIS8. Oncogene 6:867–871. PMID: 2052361

39. Ji SY, Hao JX, Li L, Zhang J, Zheng QS, et al. (2013) Expression of Inhibin-alpha is regulated synergistically by Wilms’ tumor gene 1 (WT1) and Steroidogenic Factor-1 (SF1) in Sertoli cells. PLoS ONE 8(1): e53140. doi: 10.1371/journal.pone.0053140 PMID: 23326390

40. Barbaux S, Niaudet P, Gubler MC, Grünfeld JP, Jaubert F, et al. (1997) Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 17: 467–470. doi: 10.1038/ng1297-467 PMID: 9398852

41. Klamt B, Koziell A, Poulat F, Wieacker P, Scambler P, et al. (1998) Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/−KTS splice isoforms. Hum Mol Genet 7: 709–714. doi: 10.1093/hmg/7.4.709 PMID: 9499425

42. Benz K, Plank C, Amann K, Mucha B, Dorr HG, et al. (2006) Hypergonadotropic hypogonadism and renal failure due to WT1 mutation. Nephrol Dial Transplant 21: 1716–1718. doi: 10.1093/ndt/gfl023 PMID: 16476716

43. Melo KFS, Martin RM, Costa EMF, Carvalho FM, Jorge AA, et al. (2002) An unusual phenotype of Frasier Syndrome due to IVS9 +4C>F mutation in the WT1 gene: Predominantly male ambiguous genitalia and absence of gonadal dysgenesis. J Clin Endocrinol Metab 87: 2500–2505. doi: 10.1210/jcem.87.6.8521 PMID: 12050205

44. Bor YC, Swartz J, Morrison A, Rekosh D, Ladomery M, et al. (2006) The Wilms’ tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron. Genes Dev 20: 1597–1608. doi: 10.1101/gad.1402306 PMID: 16738405

45. Wells J, Rivera MN, Kim WJ, Starbuck K, Haber DA (2010) The predominant WT1 isoform (+KTS) encodes a DNA binding protein targeting the planar cell polarity gene Scribble in renal podocytes. Mol Cancer Res 8: 975–985. doi: 10.1158/1541-7786.MCR-10-0033 PMID: 20571064